For the third straight year, the US Food and Drug Administration has reached a mark of at least 40 approvals of novel drugs and therapeutic biologics after greenlighting Alnylam Pharmaceuticals Inc.'s Givlaari (givosiran) SK Life Science Inc.'s Xcopri (cenobamate) for the US market.
A major supplemental approval went to AstraZeneca PLC's Calquence (acalabrutinib) for a chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)...





